Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients

Next Previous
Search
Trial Profile

A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levofloxacin (Primary) ; Tobramycin
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Horizon Pharma; Mpex Pharmaceuticals

Most Recent Events

  • 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
  • 24 May 2017 Results of pooled prespecified analysis of MPEX204,MPEX207 and MPEX209 studies presented at the 113th International Conference of the American Thoracic Society.
  • 10 Jun 2016 Results presented at the 39th European Cystic Fibrosis Conference 2016, according to a Raptor Pharmaceutical Corp. media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top